New Anticoagulant Agents: Incidence of Adverse Drug Reactions and New Signals Thereof
| Autor: | Carlos Treceño-Lobato, Luis H. Martín Arias, Francisco Corzo-Delibes, Raquel Martínez-García, Maria-Isabel Jimenez-Serrania |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Administration Oral Hemorrhage 030204 cardiovascular system & hematology Dabigatran Cohort Studies 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Edoxaban Surveys and Questionnaires Internal medicine medicine Humans Aged Aged 80 and over Pharmacies Rivaroxaban Acenocoumarol business.industry Incidence Warfarin Anticoagulants Hematology Odds ratio medicine.disease Cross-Sectional Studies chemistry Spain Female Apixaban Cardiology and Cardiovascular Medicine business Adverse drug reaction 030215 immunology medicine.drug |
| Zdroj: | Seminars in Thrombosis and Hemostasis. 45:196-204 |
| ISSN: | 1098-9064 0094-6176 |
| DOI: | 10.1055/s-0038-1657783 |
| Popis: | The aim of this study was to evaluate the adverse drug reaction (ADR) incidence rate and new signals thereof for classic compared with new anticoagulants in real-life ambulatory settings. The authors performed an observational cross-sectional study in two cohorts of surveyed patients treated with vitamin K antagonists (VKAs; acenocoumarol or warfarin) or nonvitamin K antagonist oral anticoagulants (NOACs; apixaban, edoxaban, rivaroxaban, dabigatran etexilate). Descriptive, clinical, and ADRs data were reported and analyzed through a bivariate analysis (odds ratio [OR]) to compare the ADRs incidence rate and an adaptation of Bayesian methodology (false discovery rate [FDR] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|